ALVOTECH |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.3 USD | +0.11% |
|
-4.11% | +15.77% |
| Apr. 30 | Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals | MT |
| Apr. 30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 353M | Sales 2025 * | 606M | Capitalization | 3.73B |
|---|---|---|---|---|---|
| Net income 2024 * | -149M | Net income 2025 * | 30M | EV / Sales 2024 * | 14.7 x |
| Net Debt 2024 * | 1.46B | Net Debt 2025 * | 1.28B | EV / Sales 2025 * | 8.26 x |
| P/E ratio 2024 * |
-22.4
x | P/E ratio 2025 * |
129
x | Employees | 999 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alvotech
More recommendations
More press releases
| 1 day | -0.60% | ||
| 1 week | -4.11% | ||
| Current month | -8.34% | ||
| 1 month | +8.58% | ||
| 3 months | -15.35% | ||
| 6 months | +47.67% | ||
| Current year | +15.77% |
1 week
13.22
13.72
1 month
12.4014.76
Current year
11.0118.00
1 year
6.7018.00
3 years
5.2018.00
5 years
5.2018.00
10 years
5.2018.00
| Managers | Title | Age | Since |
|---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 12-12-31 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 20-01-31 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 69 | 22-06-15 |
Helga Zharov
LAW | General Counsel | 57 | 20-04-30 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-12 | 13.29 | -0.60% | 75 109 |
| 24-05-14 | 13.35 | +0.45% | 76,613 |
| 24-05-13 | 13.29 | -0.60% | 75,109 |
| 24-05-10 | 13.37 | -1.69% | 55,205 |
| 24-05-09 | 13.6 | +0.44% | 41,632 |
End-of-day quote Nasdaq, May 12, 2024
More quotes
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Companyâs pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Calendar
2024-05-20
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
13.35
USD
Average target price
16.5
USD
Spread / Average Target
+23.60%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.77% | 3.73B | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +47.36% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- ALVO Stock
